Nabumetone Articles
Court rejects Teva's motion to prevent Watson launch of generic Seasonique; nabumetone OKed; Mylan Copaxone judgment
20 June 2011
Gilead files patent infringement suit against Lupin over Ranexa; Mylan’s generic nabumetone cleared by FDA
16 July 2010
GSK results in line with company guidance; shares fall on 16% drop in 4th-qtr income
23 February 2004
GSK settles Relafen antitrust litigation
16 February 2004
GSK to settle Relafen antitrust litigation
16 February 2004
Teva gains rights to GSK leukemia drug
7 July 2003
Teva settles nabumetone litigation with GSK
5 May 2003
IVAX gets US OK for generic Relafen
3 February 2003
Copaxone driving Teva revenue growth
6 May 2002
Sweden's Meda buys rights to GSK's Relifex
5 September 2001
Teva wins Relafen case; generic launch imminent
16 August 2001
Opponents of Claritin bill claim Senate win
5 July 2000
Glaxo SmithKline, an R&D powerhouse and global number one
17 January 2000
Anti-S 1172 campaign underway in three states
4 August 1999
"Tangible changes" in US market growth rate
30 July 1999
Coalition opposes patent extension bill
15 June 1999
Currency Hits SmithKline Beecham Sales And Profits
17 February 1998
GW-SB Merger Will Create R&D Superpower
5 February 1998
Upbeat UK Companies At Goldman Sachs Conference
17 June 1997
SmithKline Beecham 3rd Qtr Earnings Leap 20%
28 October 1996
US NAPM Slams "Pediatric Research" Patent Extensions Plans
14 October 1996
Rheumatoid Arthritis And Disease Management
22 April 1996
SB Trading Profit Up 19% On New Prods
26 February 1996
Global Rx-To-OTC Switching Study
27 November 1995
SmithKline Beecham Meets Expectations In 1995 3rd Qtr
30 October 1995
Beleaguered Dutch Pharma Market Manages 5% Growth
21 August 1995
Disease ManagementThe Way Forward
15 May 1995
20 Leading US Drugs' Price Increases Slammed
27 March 1995
For SmithKline Beecham 1994 Was "Successful Year"
27 February 1995
Analysts Upgrade SmithKline Beecham
31 October 1994
Benefits From PBM/MPC Acquisitions Assessed
15 August 1994
SB Lifts 2nd Qtr Earnings 20%
25 July 1994
SB Sets US Price For Famvir At Same Level As Zovirax
18 July 1994
EXTRAORDINARY INCOME BOOSTS FUJISAWA IN 1994
30 May 1994
SMITHKLINE BEECHAM PLEASED WITH RESULTS
28 February 1994
LIKELY IMPACT ON DRUG FIRMS OF ITALIAN REFORMS
17 January 1994
DRUGMAKERS IN ITALY PANIC ON NEW SALES FEARS
10 January 1994
MUSCULOSKELETAL MARKET TO DECLINE
6 December 1993
EUROPEAN STOCK COMMENT
29 November 1993
SMITHKLINE BEECHAM ADVANCES IN 3rd QTR
25 October 1993
US DRUGSTORE AUDIT DATA FOR JULY
6 September 1993
ADAPTING TO HEALTH CARE REFORM THE SB WAY
17 May 1993
SMITHKLINE BEECHAM "EXCELLENT PROGRESS"
26 April 1993
SB BEECHAM RESULTS; EXPLOITS STRENGTHS
1 March 1993
NEW YORK STOCK COMMENT
7 December 1992
stock commentary: Europe
1 June 1992
US NEW PRESCRIPTI0N DRUG SALES IN 1991
13 April 1992
UK DRUG STOCKS BULL RUN OVER?
10 February 1992
DECEMBER US APPROS REVIEWED
20 January 1992
STOCK MARKET COMMENTARY: EUROPE
13 January 1992
OPPORTUNE TIME FOR SB RELAFEN APPRO
13 January 1992
US FDA BEATS 1990 DRUG APPROVALS IN 1991
13 January 1992
YEAR-END FDA APPROVALS
6 January 1992
Showing 1-65 of 65 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
